Research map: A real-world pharmacovigilance analysis of cardiac adverse events associated with newer antibody-drug conjugates for hematological malignancies in adults: A disproportionality analysis from FDA adverse event reporting system database

Back to the article

Papers in this map

  1. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial · Paolo Fabrizio Caimi · 2021 · 443 citations · Cited by this paper
  2. Medication review in cancer pain management: A patient safety framework for optimizing pain control and reducing medication-related harm/adverse drug events · 2026 · Related
  3. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group · A.-L. Taksin · 2006 · 296 citations · Cited by this paper
  4. Remote collection of patient-reported quality of life outcomes via text messaging in cancer patients receiving oral anti-cancer therapy · 2026 · Related
  5. Empirical estimation of under-reporting in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) · Yasser M. Alatawi · 2017 · 204 citations · Cited by this paper
  6. Updates in the pharmacologic management of various Castleman disease subtypes: A comprehensive review · 2026 · Related
  7. A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers · Kaifeng Liu · 2024 · 191 citations · Cited by this paper
  8. Clinical outcomes in HTA appraisal reports of oncology medicines in Portugal: A cross-sectional analysis · 2026 · Related
  9. A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System · Yamin Shu · 2022 · 164 citations · Cited by this paper
  10. Failure mode and effects analysis of hazardous drugs preparation workflows using isolators with contextual evaluation of laminar airflow cabinets in hospital pharmacy · 2026 · Related
  11. Primary Endothelial Damage Is the Mechanism of Cardiotoxicity of Tubulin-Binding Drugs · Igor Mikaelian · 2010 · 65 citations · Cited by this paper
  12. Pharmaceutical services in pediatric oncology: A scoping review · 2026 · Related
  13. Effect of inotuzumab ozogamicin on the QT interval in patients with haematologic malignancies using QTc‐concentration modelling · Jennifer E. Hibma · 2018 · 17 citations · Cited by this paper
  14. Pharmacology-Guided venetoclax dose reduction with azacitidine in older or unfit acute myeloid leukemia: A North African experience from a Moroccan single-center cohort and exploratory hospital cost-effectiveness analysis · 2026 · Related
  15. Cardiac toxicity of brentuximab vedotin: a real-word disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database · Chengjie Ke · 2024 · 9 citations · Cited by this paper
  16. Long term stability study of cisplatin in polyolefin infusion bags in dose banding conditions using eco-friendly hydrophilic interaction chromatography and colorimetry methods · 2026 · Related
  17. Acute Left Ventricular Dysfunction Following Gemtuzumab Ozogamicin in Two Pediatric AML Patients · Kevin Owen McNerney · 2021 · 7 citations · Cited by this paper
  18. Practical considerations in the management of patients with atrial fibrillation/flutter and hematologic malignancies · 2026 · Related
  19. Adverse events of antibody-drug conjugates: comparative analysis of agents with a common payload using the adverse event spontaneous reporting database · Kenta Yamaoka · 2025 · 7 citations · Cited by this paper
  20. Personalised treatment in hpv-positive oropharyngeal squamous cell cancer: Insights from molecular biology to clinical trials · 2026 · Related
  21. Caution the arrhythmia association with antibody-drug conjugates: a pharmacovigilance study · Xiaolin Li · 2021 · 6 citations · Cited by this paper
  22. Unveiling cardiovascular and respiratory toxicities with monoclonal antibodies in multiple myeloma: disproportionality analysis from the FDA Adverse Event Reporting System · María Antonietta Barbieri · 2025 · 6 citations · Cited by this paper
  23. Identification of anticancer drugs associated to cancer therapy-related cardiac dysfunction: a VigiBase® disproportionality analysis · Damien Legallois · 2025 · 5 citations · Cited by this paper

Source: OpenAlex (CC0)